RiNA GmbH Acquires Roche RTS Protein Expression Portfolio

Penzberg/Germany, (PresseBox) - Roche (SIX: RO, ROG; OTCQX: RHHBY) and RiNA GmbH of Berlin have agreed to transfer the complete Roche Applied Science RTS Protein Expression portfolio to RiNA GmbH, effective September 15, 2009. RiNA will contribute its longstanding experience in the field of cell-free expression systems and continue production at the same quality standards defined by Roche. Responsible for sales, support, and distribution of the RTS portfolio worldwide will be 5 PRIME 5 PRIME GmbH of Hamburg, adding an enthusiastic, fast-growing global team of support, direct sales, and distributors. Both partners are committed to maintaining unchanged quality and price of RTS products.

"Roche Applied Science is focusing on innovative technologies in genomics, and we believe that a company specializing in proteomics will be able to develop the potential of RTS technology much faster than we can," states Manfred Baier, Head of Roche Applied Science.

Leo W. Tristram, CEO of RiNA GmbH says, "The RTS cell-free expression kits ideally complement the RiNA product portfolio and its dedicated customer-specific service for cell-free biosynthesis. Together with 5 PRIME products for purifying and detecting recombinant proteins, RTS technology will form a strong basis for joint development of innovative products in this dynamic field."

"This agreement allows us to address the attractive market for cell-free protein expression with a well established product line," states Bernd Haase, CEO of 5 PRIME. "RTS products are renowned for overcoming a key bottleneck in functional proteomics - limited access to pure proteins. The unique technology underlying RTS kits generates high protein yields and will serve as a cornerstone of 5 PRIME's proteomics line."

RiNA was founded as an outgrowth of the Institute of Biochemistry at the Free University of Berlin. RiNA successfully undertook major research & development activities in the field of prokaryotic and eukaryotic protein expression systems. RiNA has been working closely with Roche for many years and was involved in the development of RTS technology at its onset. RiNA has since built a solid reputation for high quality protein biosynthesis tools. For more information please visit www.rina-gmbh.eu.

5 PRIME was founded in 2006 in Hamburg. 5 PRIME's goal is to make daily lab work easier and more productive by providing scientists worldwide with reliable high-quality kits for molecular biology applications at attractive prices. 5 PRIME is represented in 50 countries, offering more than 220 products that cover everything from nucleic acid purification and amplification to protein expression and purification. The company's products will be complemented by the RTS portfolio.

Please visit www.5PRIME.com/rts.aspx for more information.

Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.